Shaping a new era of global health investment, policy, planning and prevention
AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.
Our advocacy takes place:
Blog Post
AVAC denounces recent proposals and actions by the US administration that signal a clear intention to defund and eliminate lifesaving global health research, development and delivery programs. If passed by Congress, proposed funding rescissions for the current year’s budget would claw back billions of Congressionally appropriated dollars for critical, life-saving programs.
report
This Issue Brief describes the impacts of the elimination and reduction of funding that supports sexually transmitted infection (STI) research, testing, and prevention programming. This funding is critically important as STI rates continue to increase globally with more than 1 million curable STIs, including chlamydia, gonorrhea, syphilis, and trichomoniasis, acquired every day. Without appropriate testing, treatment, and prevention programs, there is a risk that STI rates will continue to increase leading to more cases of infertility, pelvic inflammatory disease, and cancers.
article
AVAC and GAPP submitted written testimony for the US Senate Appropriations Subcommittee’s April 30th hearing, “Biomedical Research: Keeping America’s Edge in Innovation.”
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.
Accelerating the development and delivery of STI prevention.
Using data for smarter advocacy and high-impact campaigns.
Developing an Africa-centered network dedicated to accelerating HIV prevention research, and advancing equitable access to proven HIV prevention products.
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.
With the increased abuse of technology in surveilling and criminalizing healthcare, especially abortion and gender affirming care, more and more people are asking: is my personal health data safe? Kendra Albert, a public interest technology lawyer, discussed the current state of health data privacy, especially as it relates to people living with HIV. Participants learned basic concepts in health data privacy and what actions they can take to improve health data privacy on the state level.
AVAC denounces recent proposals and actions by the US administration that signal a clear intention to defund and eliminate lifesaving global health research, development and delivery programs. If passed by Congress, proposed funding rescissions for the current year’s budget would claw back billions of Congressionally appropriated dollars for critical, life-saving programs.